Company profile for BioXcel Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology. We are focused on utilizing cutting-edge technology & innovative research to develop high value therapeutics aimed at transforming patients’ lives. BioXcel Therapeutics employs a unique AI platform an effort to reduce thera...
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology. We are focused on utilizing cutting-edge technology & innovative research to develop high value therapeutics aimed at transforming patients’ lives. BioXcel Therapeutics employs a unique AI platform an effort to reduce therapeutic development costs and potentially accelerate timelines, while aiming to increase the possibility of success.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
555 Long Wharf Drive 12th Floor New Haven, CT 06511
Telephone
Telephone
475-238-6837
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

Global ChemShow

Not Confirmed

envelop Contact Supplier

Global ChemShow

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/14/3166033/0/en/BioXcel-Therapeutics-Announces-Positive-Results-from-Correlation-Study-Supporting-SERENITY-At-Home-Exploratory-Efficacy-Outcomes.html

GLOBENEWSWIRE
14 Oct 2025

https://www.globenewswire.com/news-release/2025/10/13/3165413/0/en/BioXcel-Therapeutics-to-Ring-Nasdaq-Closing-Bell-on-October-14-to-Celebrate-a-Transformative-Milestone-in-Neuroscience-Innovation.html

GLOBENEWSWIRE
13 Oct 2025

https://www.globenewswire.com/news-release/2025/09/18/3152274/0/en/BioXcel-Therapeutics-Regains-Compliance-with-Nasdaq-Market-Value-of-Listed-Securities-Requirements.html

GLOBENEWSWIRE
18 Sep 2025

https://www.globenewswire.com/news-release/2025/09/10/3147596/0/en/BioXcel-Therapeutics-Reports-Positive-Topline-Exploratory-Efficacy-Data-from-SERENITY-At-Home-Pivotal-Phase-3-Safety-Trial-for-Agitation-Associated-with-Bipolar-Disorders-or-Schizo.html

GLOBENEWSWIRE
10 Sep 2025

https://www.globenewswire.com/news-release/2025/09/04/3144339/0/en/BioXcel-Therapeutics-to-Present-at-the-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html

GLOBENEWSWIRE
04 Sep 2025

https://www.globenewswire.com/news-release/2025/08/26/3139590/0/en/BioXcel-Therapeutics-To-Announce-Topline-Results-from-SERENITY-At-Home-Pivotal-Phase-3-Safety-Trial-for-Acute-Treatment-of-Agitation-Associated-with-Bipolar-Disorders-or-Schizophre.html

GLOBENEWSWIRE
26 Aug 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty